health-wealth-bulletin Logo

Call me old-fashioned, but I believe valuations still matter.

It's easy to see the market hit all-time highs and want to get a little more skin in the game. It's normal to try and ride the hottest stocks higher, betting on more fast gains.

This strategy might work as a trade. But the fundamental investor in me has to remind everyone that prices matter. Paying a sky-high valuation for a flashy stock will burn you in the end more often than not.

As an example, think of Cisco Systems (CSCO) back in the early 2000s.

Cisco reaped the benefits of the dot-com boom, though it wasn't a literal "dot-com company." It made the routers and switches behind the Internet network that the dot-com companies operated on.

Cisco's position was dominant. As of 1996, it controlled 78% of the router market. And it enjoyed strong margins and returns on capital.

By early 2000, the dot-com bubble expanded, and telecom companies invested in a massive build-out of Internet and broadband networks. As investors got giddy about astronomical growth, Cisco's price-to-sales ratio soared to 63 times.

Of course, the Internet bubble burst. And wild spending on expanding the Internet ended. Cisco started losing money, and its valuation collapsed. Shares fell 86% by late 2001...

That said, all the rosy predictions about Cisco's business came true...

The company still dominates networking equipment – though not quite as thoroughly as it did at the time. Its operating income rebounded rapidly and has climbed for two and a half decades.

And in just the past 10 years, shares have returned 12.8% per year when you account for dividends.

This is a perfect example of what we call the "valuation life cycle"... A young, fast-growing company sports a high multiple. That multiple decreases as the company matures and the hype fades. But the rising earnings and the lower multiple can still combine to deliver positive returns for investors.

Cisco's operating income has grown to an average of more than $3 billion per quarter. And its valuation has compressed to less than 5 times sales.

If you had bought Cisco at its absurd valuations in early 2000, you'd have lost money over the past quarter century. But if you had bought into this business at almost any other time following the dot-com crash, you'd have done very well.

You just can't win buying at 63 times sales. Over the past 12 months, though, Cisco has traded for a reasonable price. And it's a company returning a lot of cash to shareholders.

That's why we recommended buying shares in my income-focused newsletter Income Intelligence one year ago.

We're already up around 45%.

But the message here today is to pay attention to prices. We're seeing a lot of stocks trading for nosebleed valuations... And it's going to be tough for many companies to grow enough in future years to deserve these valuations.

The much-hyped Palantir Technologies (PLTR), for example, is trading for 100 times sales.

Be careful with stories like these. You can end up losing a lot of money when the hype inevitably dies down. Instead, take a long-term approach and fill your portfolio with high-quality companies you bought at decent valuations.

Of course, finding solid companies to invest in has become much more difficult. According to my friend and 50-year Wall Street veteran Marc Chaikin, traditional metrics no longer work in today's innovation-driven, hype-fueled environment.

It all comes down to the fact that lackluster companies can deceive you with accounting tricks and make their numbers appear better than they really are.

Marc has a solution to this problem, however. He devised something called the "earnings quality" tool. Now, his subscribers can separate the trickster companies from those with genuine growth potential.

To learn more about this tool and how it can help you, click here.

What We're Reading...

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig and the Health & Wealth Bulletin Research Team
July 2, 2025

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David Eifrig
Dr. David Eifrig
Editor

Dr. Eifrig has one of the most remarkable resumes of anyone we know in this industry. After receiving his BA from the Carleton College in Minnesota, he went on to earn an MBA from Northwestern University’s Kellogg School of Management, graduating on the Dean’s List with a double major in finance and international business.

From there, Dr. Eifrig went to work as an elite derivatives trader at the investment bank Goldman Sachs. He spent a decade on Wall Street with several major institutions, including Chase Manhattan and Yamaichi (then known as the “Goldman Sachs of Japan”).

That’s when Dr. Eifrig’s career took an unconventional turn. Sick of the greed and hypocrisy of Wall Street... he quit his senior vice president position to become a doctor. He graduated from Columbia University’s post-baccalaureate pre-medicine program and eventually earned his MD with clinical honors from the University of North Carolina at Chapel Hill. While at med school, he was elected president of his class and admitted to the Order of the Golden Fleece (considered the highest honor given at UNC-Chapel Hill).

Dr. Eifrig also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotech company, Mirus, that was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine’s many conflicts, Dr. Eifrig began to look for ways he could talk directly with individuals and use his background to show them how to take control of their health and wealth. In 2008, he joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams, and Income Intelligence, the most comprehensive monthly review we know of the universe of income investments.

He is also the author of five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He also owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California.

Back to Top